TrialClinical pharmacology in drug development2018

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.

Naidong Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.